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Abstract:  The synthetic utility of 3,3’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis 
(3-oxopropanenitrile) (1) in the synthesis of some novel bis-[1,3,4-thiadiazole] 6a–g and 
bis-thiazole  10  and 13 derivatives with thieno[2,3-b]thiophene moiety is reported. 
Antimicrobial evaluation of some selected examples from the synthesized products was 
carried out and showed promising results. 
Keywords: thieno[2,3-b]thiophene; nucleophilic addition; hydrazonoyl halides;   
bis-thiadiazoles; bis-thiazoles; antimicrobial activity 
 
1. Introduction  
Thiophene compounds are well known to exhibit various biological and medicinal activities such as 
BACE1 inhibitors [1], antitubercular [2], anti-depressant [3], anti-inflammatory [4],
  anti-HIV PR 
inhibitors [5], and anti-breast cancer activities [6]. In addition, thienothiophenes have potential 
applications in a wide variety of optical and electronic systems [7–9]. Furthermore, 1,3,4-thiadiazoles 
were recently reported as highly anti-inflammatory [10,11], and anticonvulsant agents [10,12].   
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Also, thiazoles and their derivatives found application in drug development for the treatment of 
allergies [13], hypertension [14], inflammation [15], schizophrenia [16], bacterial [17] and HIV 
infections [18]. Encouraged by all these findings and in continuation of our ongoing research program 
investigating the utilization of compound 1 as versatile and useful building blocks for the synthesis of 
a wide variety of bis-heterocycles systems [19,20], we report in the present work an efficient and rapid 
method for the synthesis of a series of thienothiophene pendant to thiadiazole or thiazole moieties. 
2. Results and Discussion  
The nucleophilic addition of thieno[2,3-b]thiophene 1 [19] to phenyl isothiocyanate in DMF, in the 
presence of potassium hydroxide, afforded the corresponding potassium salt 2. Heterocyclisation of the 
intermediate 2 with hydrazonoyl chlorides 3a [21] or 3b–d [22] or 3e–g [23] furnished in each case, 
one isolable product (as tested by TLC). The reaction products were identified as bis-[1,3,4]-thiadiazole 
structures 6a–g (Scheme 1).  
Scheme 1. Synthesis of bis-[1,3,4]-thiadiazole structures 6a–g. 
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The structure of the products 6a–g was determined from spectroscopic as well as elemental 
analytical data. Thus, compound 6a, taken as a typical example, showed absorption bands at 1674 and 
2199 cm
−1 corresponding to C=O and C≡N groups, respectively. Its 
1H NMR spectrum revealed the 
absence of CH2 protons of compound 1 and showed signals at δ 2.49 due to CH3 protons, in addition to 
an aromatic multiplet in the region δ 7.57–7.97. The aforementioned results indicate that the reaction 
proceeds via S-alkylation [24] to give S-alkylated intermediate 4 which cyclized in situ under the 
employed reaction conditions to give intermediate 5. Elimination of two aniline molecules from 5 gave 
the desired product 6 (Scheme 1). 
Scheme 2. Synthesis of 3,3’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(3-oxo-2-(4-
(2-oxo-2H-chromen-3-yl)-3-phenylthiazol-2(3H)-ylidene)propanenitrile (10). 
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Next, the reactivity of the potassium salt 2 towards 3-(2-bromoacetyl)-2H-chromen-2-one (7) [25,26] 
was also investigated. Thus, treatment of potassium salt 2 with compound 7 gave one product that was 
identified as 3,3’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(3-oxo-2-(4-(2-oxo-2H-chromen-3-Int. J. Mol. Sci. 2012, 13                 
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yl)-3-phenylthiazol-2(3H)-ylidene)propanenitrile) (10) as shown in Scheme 2. The reaction proceeds 
via nucleophilic displacement of bromide to give S-alkylated intermediate 8, followed by nucleophilic 
addition of (PhNH) group to carbonyl group of chromen-2-one ring to give the respective intermediate 9. 
Dehydration of the latter intermediate gave bis-thiazole derivative 10 as the final product. The IR 
spectrum of the isolated product showed absorption bands at 2195, 1647 and 1724 cm
−1 due to nitrile 
function and carbonyl groups, respectively. Its 
1H NMR spectrum showed singlet signal at δ 2.49 ppm 
due to methyl protons, in addition to aromatic multiplets in the region δ 7.02–8.6 ppm.  
Scheme 3. Synthesis of diethyl 2,2’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-
diyl)bis(1-cyano-2-oxoethan-2-yl-1-ylidene))bis(4-methyl-3-phenyl-2,3-dihydrothiazole-5-
carboxylate) (13). 
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Similarly, treatment of the potassium salt 2 with ethyl 2-chloro-3-oxobutanoate afforded diethyl 
2,2’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1-ylidene))bis(4-
methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate) (13) as outlined in Scheme 3.The bis-thiazole 
structure 13 was confirmed from its elemental analyses and spectral data. The IR spectrum of compound 
13 revealed absorption bands at 2206, 1713 and 1643 cm
−1 due to nitrile function and two carbonyl 
groups, respectively. Its 
1H-NMR spectrum showed a triplet signal at δ 1.30 (J = 7.2 Hz) due to CH3 
protons, two singlet signal at δ 2.24 and 2.49 characteristics for two methyl protons, a quartet signal at 
δ 4.32 (J = 7.2 Hz) due to CH2 protons, in addition to an aromatic multiplet in the region δ 7.62.  
A proposed mechanism for the formation of the bis-thiazole structure 13 is depicted in Scheme 3. The 
foregoing spectral data supported the proposed structure 13  and ruled out the other bis-thiazole 
structure 14 (Scheme 3). 
3. Experimental Section  
All melting points were measured on a Gallenkamp melting point apparatus (Weiss-Gallenkamp, 
London, UK). The infrared spectra were recorded in potassium bromide disks on a pye Unicam SP 
3300 and Shimadzu FT IR 8101 PC infrared spectrophotometers (Pye Unicam Ltd. Cambridge, 
England and Shimadzu, Tokyo, Japan, respectively). The NMR spectra were recorded on a BRUKER 
VX-500 NMR spectrometer (Varian, Palo Alto, CA, USA). 
1H spectra were run at 500 MHz in 
deuterated dimethyl sulfoxide (DMSO-d6). Chemical shifts were related to that of the solvent. 
Elemental analyses were carried out at the Micro-analytical Center of Cairo University, Giza, Egypt. 
The biological evaluation of the products 6a–g and 10 were carried out in the Medical Mycology 
Laboratory of the Regional Center for Mycology and Biotechnology of Al-Azhar University, Cairo, 
Egypt. Thieno[2,3-b]thiophene 1 [19], and hydrazonoyl chlorides 3a [21], 3b–d [22], 3e–g [23], and  
3-(2-bromoacetyl)-2H-chromen-2-one (7)
 [25,26] were prepared following the literature procedure. 
Reactions of Compound 1 with Hydrazonoyl Halides 3a or 3b-d or 3e-g or 3-(2-bromoacetyl)-2H-
chromen-2-one (7) 
General Procedure: To a stirred solution of potassium hydroxide (0.11 g, 2 mmol) in 20 mL DMF was 
added compound 1  (0.302 g, 1 mmol). After stirring for 30 min, phenyl isothiocyanate (0.27 g, 2 
mmol) was added to the resulting mixture. Stirring was continued for 6 h, and then the appropriate 
hydrazonoyl chlorides 3a–g (2 mmol) or 3-(2-bromoacetyl)-2H-chromen-2-one (7) (0.534 g, 2 mmol) 
or ethyl 2-chloro-3-oxobutanoate (0.329 g, 2 mmol) was added portion-wise over a period of 30 min. 
After the addition was complete, the reaction mixture was stirred for additional 12 h, during which the 
hydrazonoyl chloride or 3-(2-bromoacetyl)-2H-chromen-2-one went into solution and a yellow product 
precipitated. The solid product was filtered off, washed with EtOH and dried, Recrystallization from 
DMF/EtOH (3:1) afforded the corresponding bis-[1,3,4]thiadiazole derivatives 6a–g or bis-thiazole 
derivatives 10 or 13, respectively. Int. J. Mol. Sci. 2012, 13                 
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3,3’-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(2-(3,5-diphenyl-1,3,4-thiadiazol-2(3H)-
ylidene)-3-oxopropanenitrile) (6a). Yield (61%), m.p. 276 °C; IR (KBr) νmax: 2905 (aliphatic CH), 
2199 (C≡N), 1674 (C=O) cm
−1; 
1H-NMR (DMSO-d6): δ 2.49 (s, 6H, 2CH3), 7.57–7.97 (m, 20H, ArH). 
MS m/z (%): 775 (M
+, 0.16), 774 (0.14), 471 (46.73), 304 (4.13), 77 (70.79). Anal. Calcd for 
C42H26N6O2S4 (774.95): C, 65.09; H, 3.38; N, 10.84. Found: C, 65.01; H, 3.45; N, 10.90%.  
Diethyl 5,5’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- 
ylidene))bis(4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate)(6b). Yield (52%), m.p. > 300 °C; 
IR (KBr) νmax: 2982 (aliphatic CH), 2199 (C≡N), 1744 and 1674 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): 
δ 1.33 (s, 6H, 2CH3, J = 6.9 Hz), 2.49 (s, 6H, 2CH3), 4.44 (q, 4H, 2CH2, J = 6.9 Hz),7.53–7.92 (m, 
10H, ArH). MS m/z (%): 767 (M
+, 1.57), 167 (19.92), 149 (36.71), 77 (7.77). Anal. Calcd for 
C36H26N6O6S4 (766.89): C, 56.38; H, 3.42; N, 10.96. Found: C, 56.30; H, 3.36; N, 10.88%. 
Diethyl 5,5’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- 
ylidene))bis(4-p-tolyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate) (6c). Yield (66%), m.p. > 300 °C; 
IR (KBr) νmax: 2986 (aliphatic CH), 2203 (C≡N), 1747 and 1674 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): 
δ 1.35 (s, 6H, 2CH3,  J  = 7.0 Hz), 2.42 (s, 6H, 2CH3), 2.52 (s, 6H, 2CH3),4.46 (q, 4H, 2CH2,  
J = 7.0 Hz),7.41 (d, 4H, J = 8.0 Hz), 7.62 (d, 4H, J= 8.0 Hz). MS m/z (%): 793 (3.44), 222 (4.85), 221 
(4.55), 167 (9.11), 91 (50.33), 77 (51.22). Anal. Calcd for C38H30N6O6S4 (794.94): C, 57.41; H, 3.80; 
N, 10.57. Found: C, 57.52; H, 3.88; N, 10.66 %. 
Diethyl 5,5’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- 
ylidene))bis(4-(4-chlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate)(6d).  Yield (53%),   
m.p. > 300 °C; IR (KBr) νmax: 2986 (aliphatic CH), 2206 (C≡N), 1744 and 1674 (2C=O) cm
−1;  
1H-NMR (DMSO-d6): δ 1.37 (s, 6H, 2CH3, J = 7.0 Hz), 2.52 (s, 6H, 2CH3), 4.47 (q, 4H, 2CH2,  
J = 7.0 Hz),7.73 (d, 4H, J= 10.0 Hz), 7.84 (d, 4H, J = 10.0 Hz). MS m/z (%): 835 (M
+, 2.81), 334 
(6.05), 168 (8.37), 112 (6.37), 111 (23.38), 77 (39.48). Anal. Calcd for C36H24Cl2N6O6S (835.78): C, 
51.73; H, 2.89; N, 10.06. Found: C, 51.67; H, 2.79; N, 10.12%. 
3,3’-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(2-(5-acetyl-3-p-tolyl-1,3,4-thiadiazol-2(3H)-
ylidene)-3-oxopropanenitrile)(6e). Yield (52%), m.p. 240 °C; IR (KBr) νmax: 2199 (C≡N), 1690 and 
1674 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): δ 2.29 (s, 6H, 2CH3), 2.45 (s, 6H, 2CH3), 2.50 (s, 6H, 
2CH3), 7.22 (d, 4H, J = 8.5 Hz), 7.33 (d, 4H, J = 8.5 Hz). MS m/z (%): 732 (0.04), 647 (0.06), 221 
(2.03), 166 (1.33), 106 (100.0), 91, (58.18), 77 (84.54). Anal. Calcd for C36H26N6O4S4 (734.89): C, 
58.84; H, 3.57; N, 11.44. Found: C, 58.77; H, 3.49; N, 11.38%. 
3,3’-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(2-(5-acetyl-3-(4-chlorophenyl)-1,3,4-
thiadiazol-2(3H)-ylidene)-3-oxopropanenitrile)(6f). Yield (49%), m.p. 295 °C; IR (KBr) νmax: 2199 
(C≡N), 1693 and 1655 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): δ 2.41 (s, 6H, 2CH3), 2.52 (s, 6H, 2CH3), 
7.72 (d, 4H, J = 8.8 Hz), 7.84 (d, 4H, J = 8.8 Hz). MS m/z (%): 776 (3.02), 500 (3.36), 471 (9.6), 304 
(3.99), 276 (6.27), 166 (10.71), 112 (6.32), 111 (16.73). Anal. Calcd for C34H20Cl2N6O4S4 (775.73): C, 
52.64; H, 2.60; N, 10.83. Found: C, 52.58; H, 2.54; N, 10.77%. 
3,3’-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(2-(5-acetyl-3-(3-chlorophenyl)-1,3,4-
thiadiazol-2(3H)-ylidene)-3-oxopropanenitrile)(6g). Yield (49%), m.p. > 300 °C; IR (KBr) νmax: 2199 Int. J. Mol. Sci. 2012, 13                 
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(C≡N), 1690 and 1647 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): δ 1.89 (s, 6H, 2CH3), 2.49 (s, 6H, 2CH3), 
6.97–8.00 (m, 8H, ArH). MS m/z (%):  771 (3.28), 304 (6.34), 166 (22.08), 112 (13.36), 111 (18.98). 
Anal. Calcd for C34H20Cl2N6O4S4 (775.73): C, 52.64; H, 2.60; N, 10.83. Found: C, 52.55; H, 2.52;  
N, 10.74%. 
3,3’-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(3-oxo-2-(4-(2-oxo-2H-chromen-3-yl)-3-
phenylthiazol-2(3H)-ylidene)propanenitrile) (10). Yield (68%), m.p. > 300 °C; IR (KBr) νmax: 2195 
(C≡N), 1724 and 1647 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): δ 2.49 (s, 6H, 2CH3), 7.02–8.6 (m, 22H, 
ArH). MS m/z (%): 909 (2.45), 166 (2.75), 145 (4.05), 77 (15.41). Anal. Calcd for C50H28N4O6S4 
(909.04): C, 66.06; H, 3.10; N, 6.16. Found: C, 66.15; H, 3.21; N, 6.25%. 
Diethyl 2,2’-(2,2’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- 
ylidene))bis(4-methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate) (13). Yield (44%), m.p. 278–280 °C; 
IR (KBr) νmax: 2986 (aliphatic CH), 2206 (C≡N), 1713 and 1643 (2C=O) cm
−1; 
1H-NMR (DMSO-d6): 
δ 1.30 (t, 6H, 2CH3,  J  = 7.2 Hz), 2.24 (s, 6H, 2CH3), 2.49 (s, 6H, 2CH3), 4.32 (q, 4H, 2CH2,  
J = 7.2 Hz),7.62 (s, 10H, ArH). Anal. Calcd for C40H32N4O6S4 (792.97): C, 60.59; H, 4.07; N, 7.07. 
Found: C, 60.48; H, 4.16; N, 7.15%. 
3.1. Antimicrobial Evaluation 
The newly synthesized target compounds (6a–g and 10) were evaluated for their in vitro 
antibacterial activity against Staphylococcus aureus (SA) and Bacillis subtilis (BS) as examples of 
Gram-positive bacteria and Pseudomonas aeruginosa (PA) and Escherichia coli (EC) as examples of 
Gram-negative bacteria. They were also evaluated for their in vitro antifungal potential against 
Aspergillus fumigatus (AF), Geotrichum candidum (GC), Candida albicans (CA) and Syncephalastrum 
racemosum (SR) fungal strains. The organisms were tested against the activity of solutions of 
concentrations (5 μg/mL) and using inhibition zone diameter (IZD) in mm as criterion for the 
antimicrobial activity (agar diffusion method). The fungicides Itraconazole,  Clotrimazole and the 
bactericides Penicillin G, Streptomycin were used as references to evaluate the potency of the tested 
compounds under the same conditions. The results are depicted in Table 1.  
The results depicted in Table 1 revealed that most of the tested compounds displayed variable 
inhibitory effects on the growth of the tested Gram-positive bacteria and Gram-negative   
bacteria strains and also against fungal strains. In general, most of the tested compounds revealed 
better activity against the Gram-positive bacteria rather than the Gram-negative bacteria: Compounds 
6a, 6c–d and 10 exhibited almost no activity against Syncephalastrum racemosum and Pseudomonas 
aeruginosa; Compounds 6b and 6e–g exhibited almost no activity against Candida albicans. 
Compounds 6e and 6g exhibited almost no activity against Pseudomonas aeruginosa; Compounds 6d, 
6f and 10 showed comparatively good activity against all the bacterial and fungal strains. The good 
activity of 6d and 6f is attributed to the presence of pharmacologically active 4-chlorophenyl at 
position 4 of the thiadiazole ring. Int. J. Mol. Sci. 2012, 13                 
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Table 1. Antibacterial and antifungal activities of the synthesized compounds (6a–g) and 10.  
Sample / Tested 
Organism 
6a 6b 6c 6d 6e 6f  6g  10  Standard 
Fungi                 Itraconazole  Clotrimazole 
Aspergillus fumigatus 
(AF) 
11.7 ± 0.2  15.4 ± 0.09  13.3 ± 0.2  16.4 ± 0.3  9.3 ± 0.2  17.4 ± 0.08  12.2 ± 0.09  14.3 ± 0.2  28.5 ± 0.05  26 ± 0.1 
Geotrichum candidum 
(GC) 
13.5 ± 0.1  14.9 ± 0.05  14.4 ± 0.1  18.1 ± 0.08  11.4 ± 0.1  18.3 ± 0.3  14.4 ± 0.03  16.7 ± 0.08  27.1 ± 0.06  23.1 ± 0.03 
Candida albicans (CA)  10.4 ± 0.08  NA  10.2 ± 0.09  13.7 ± 0.05  NA  NA  NA  11.9 ± 0.1  26.1 ± 0.02  18.3 ± 0.01 
Syncephalastrum 
racemosum (SR) 
NA  12.1 ± 0.08  NA  NA  8.2 ± 0.09  14.2 ± 0.08  9.2 ± 0.08  NA  22.3 ± 0.09  20.5 ± 0.02 
Gram Positive Bacteria   Penicillin  G  Streptomycin 
Staphylococcus aureus 
(SA) 
11.2 ± 0.1  17.9 ± 0.05  11.3 ± 0.05  15.4 ± 0.5  9.4 ± 0.05  18.9 ± 0.01  13.8 ± 0.1  13.4 ± 0.3  29.4 ± 0.08  25.1 ± 0.08 
Bacillis subtilis (BS)  13.7 ± 0.07  16.1 ± 0.01  9.0 ± 0.08  18.4 ± 0.1  10.6 ± 0.08  20.9 ± 0.03  16.6 ± 0.03  14.7 ± 0.09  32.5 ± 0.06  29.1 ± 0.04 
Gram Negative Bacteria   Penicillin  G  Streptomycin 
Pseudomonas 
aeruginosa (PA) 
NA  10.1 ± 0.01  NA  NA  NA  12.1 ± 0.01  NA  NA  28.3 ± 0.05  24.3 ± 0.08 
Escherichia coli (EC)  8.3 ± 0.09  14.5 ± 0.2  10.1 ± 0.07  13.7 ± 0.05  7.4 ± 0.07  15.2 ± 0.5  9.5 ± 0.2  10.9 ± 0.2  33.5 ± 0.7  25.6 ± 0.04 
NA: No activity, data are expressed in the form of mean ± SD. Mean zone of inhibition in mm ± Standard deviation beyond well diameter (6 mm) produced on a range of 
environmental and clinically pathogenic microorganisms using (5 mg/mL) concentration of tested samples. Int. J. Mol. Sci. 2012, 13                 
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4. Conclusions 
In conclusion, the reactivity of diethyl 3,3’-(3,4-dimethylthieno[2,3-b]thiophene-2,5-diyl)bis 
(3-oxopropanenitrile) (1) was investigated as a versatile and readily accessible building block for the 
synthesis of new bis-heterocycles incorporating thieno[2,3-b]thiophene moiety of biological and 
pharmaceutical importance. 
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